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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a multifactorial fatal motoneuron disease without a cure. Ten percent
of ALS cases can be pointed to a clear genetic cause, while the remaining 90% is classified as sporadic. Our
study was aimed to uncover new connections within the ALS network through a bioinformatic approach, by
which we identified C13orf18, recently named Pacer, as a new component of the autophagic machinery and
potentially involved in ALS pathogenesis.
Methods: Initially, we identified Pacer using a network-based bioinformatic analysis. Expression of Pacer was
then investigated in vivo using spinal cord tissue from two ALS mouse models (SOD1G93A and TDP43A315T)
and sporadic ALS patients. Mechanistic studies were performed in cell culture using the mouse motoneuron cell line
NSC34. Loss of function of Pacer was achieved by knockdown using short-hairpin constructs. The effect of Pacer
repression was investigated in the context of autophagy, SOD1 aggregation, and neuronal death.
Results: Using an unbiased network-based approach, we integrated all available ALS data to identify new functional
interactions involved in ALS pathogenesis. We found that Pacer associates to an ALS-specific subnetwork composed of
components of the autophagy pathway, one of the main cellular processes affected in the disease. Interestingly, we
found that Pacer levels are significantly reduced in spinal cord tissue from sporadic ALS patients and in tissues from two
ALS mouse models. In vitro, Pacer deficiency lead to impaired autophagy and accumulation of ALS-associated protein
aggregates, which correlated with the induction of cell death.
Conclusions: This study, therefore, identifies Pacer as a new regulator of proteostasis associated with ALS pathology.
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Background
Amyotrophic lateral sclerosis (ALS) is the most com-
mon adult motoneuron disease that causes a progres-
sive paralysis due to the selective loss of motoneurons
in the motor cortex, brainstem motor nucleus, and
spinal cord [1]. In recent years, a growing number of
genetic loci have been associated with ALS and other
complex diseases (reviewed in [2, 3]). The first
mutations identified as a cause of familial ALS (fALS)
mapped to SOD1 (superoxide dismutase 1), whereas
mutations in the TARDBP gene, coding for Tar DNA
binding protein 43 (TDP43), one of the most com-
mon components of protein aggregates in ALS cases,
were identified years later [4]. Since then, the number
of genes associated with ALS has significantly in-
creased (reviewed in [2]). The recent discovery of
hexanucleotide G4C2 repeat expansions in the intronic
region of C9orf72 as a common genetic cause of fALS
[5] and frontotemporal dementia (FTD) has profoundly
changed our understanding of ALS, explaining almost
40% of the familial cases, in addition to near 10% of
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sporadic ALS (sALS) [5, 6]. ALS is now considered to be
part of a spectrum of neurological disorders instead of
simply a neuromuscular disease. Understanding shared
pathophysiological mechanisms of sALS and fALS
promises the finding of effective therapies for both forms
of the disease. Defective cellular processes identified thus
far to be responsible for the ALS and the related FTD in-
clude (i) alterations to proteostasis control (protein quality
control, including proteasomal degradation, autophagy
and endoplasmic reticulum (ER) stress), (ii) mitochondrial
dysfunction, (iii) cytoskeletal dynamics and axonal trans-
port, (iv) RNA homeostasis, and (v) DNA damage
response (reviewed in [3, 7, 8]). Macroautophagy, here re-
ferred to as autophagy, is an evolutionarily conserved
process that consists of vesicles termed autophagosomes
to deliver intracellular cargo to the lysosome, including
long-lived cytosolic proteins, damaged organelles, and
protein aggregates [9, 10]. Most cell types, including neu-
rons, operate under constitutive autophagy [11], which is
thought to have a vital role in maintaining their metabolic
and proteostatic balance [12–14]. In this context, defects
in the endolysosomal pathway or autophagy-related genes
have been associated with diverse neurodegenerative
diseases, including Alzheimer’s disease (AD), Hunting-
ton’s disease (HD), Parkinson’s disease (PD), as well
as ALS [15, 16]. Mutations in several genes coding
for proteins involved in autophagy or other mem-
brane trafficking pathways have been found in ALS
patients, including SQSTM1 and OPTN, which encode
the selective autophagy receptors SQSTM1/p62 and
optineurin, respectively, and ALS2 that encodes alsin2,
which participates in membrane trafficking, as well as
TBK1 (TANK-binding kinase 1), a kinase involved in
autophagy-mediated degradation of ubiquitinated car-
gos [17–19]. C9orf72 was also shown to participate in
the autophagy process [20]. Targeting autophagy with
genetic and pharmacological approaches has indicated
that the pathway may have pathogenic or protective
roles depending on the disease stage and cell type
analyzed [21–23]. Thus, defects in autophagy and
endolysosomal pathways may underlay an important
part of the etiology of the disease.
The rise of high-throughput experimental approaches
such as genomics, transcriptomics, and proteomics pro-
vides new datasets for ALS and other neurodegenerative
diseases. Recent comprehensive studies proofed that
network-based analysis offers the means to unravel new
genes, pathways and disease networks associated with com-
plex disorders similar to ALS [24–29]. The convergent ana-
lysis approach, which is loosely defined as the combination
of multi-dimensional datasets with network modeling of
gene and protein interactions, provides a new way to iden-
tify genes involved in disease pathways or mechanisms even
with little or no previous evidence [26, 27]. We applied this
approach to the data available for ALS and selected the
C13orf18 gene for further experimental studies, based on (i)
its suggested participation in the human autophagy net-
work through interaction with Beclin1, one of the main
components of this pathway [30] that is known to be dys-
regulated in ALS [22], (ii) a single-nucleotide polymorph-
ism (SNP) in the 3’UTR of the C13orf18 gene
(polymorphism ID: rs2478046) found in a higher allele fre-
quency in a sALS patient cohort [31], and (iii) the fact that
the C13orf18 protein was uncharacterized and had no cel-
lular function assigned to it. Due to its sequence homology
with Rubicon (Run domain protein Beclin1 interacting and
cysteine-rich domain or KIAA0226), C13orf18 is also re-
ferred to as Rubicon-like or KIAA0226-L. However, re-
cently, Cheng et al. reported that C13orf18 positively
regulates autophagosome maturation by complex associ-
ation with UVRAG and stimulation of Vps34 kinase
activity, hence it was named Pacer (protein associated with
UVRAG as autophagy enhancer) [32].
Here we report that Pacer displays decreased expres-
sion in the terminal stage of the disease in two fALS
mouse models and notably in post-mortem spinal cord
tissue from sALS patients. Interestingly, we found Pacer
to be expressed exclusively in neurons in the spinal cord.
Using cellular models, we demonstrate that targeting
Pacer results in reduced autophagy activity, augmented
SOD1 aggregation, and sensitization of motoneurons to
cell death. Hence, our study identifies Pacer as a new
protein involved in neuronal autophagy, whose loss is
related to the selective vulnerability of motoneurons
during ALS pathogenesis.
Methods
Convergent analysis
Copy number variation (CNV) data were collected
from 4 published studies [33–36]. A total of 338 genes
associated with ALS were included in the analysis.
Additionally, genes linked to ALS were collected from
The Huge Navigator (an integrated knowledge base of
human genome epidemiology). We specifically searched
the Phenopedia page for ALS related association studies
and reported genes. Using the exact match of term
“ALS” or “motoneuron disease,” we retrieved 143 genes
annotated in the HuGE database (2011). From those,
128 genes were finally included in the analysis (14
genes were excluded from the analysis because there
were not associated with the disease upon revision)
(Additional file 1: Table S1). We uploaded the se-
lected CNV and HuGE genes into the Ingenuity
Pathway Analysis (IPA) system (Qiagen), which con-
tains protein/protein interaction (PPI) and expression
datasets. We ran a “core analysis” approach and ob-
tained 241 genes in 12 ALS-associated subnetworks
(Additional file 2: Table S2).
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Animals
We employed the SOD1G93A (strain 002726) and
TDP43A315T (strain 010700) transgenic mice both ob-
tained from The Jackson Laboratory as ALS mouse
models [37, 38]. The TDP43A315T received jellified food
to prevent the premature death by intestinal dysmotility
and allowed the motor degeneration phenotype to de-
velop [39]. The animal care and all animal experiments
were performed according to procedures approved by
“Guide for the Care and Use of Laboratory Animals”
(Commission on Life Sciences, National Research
Council. National Academy Press 1996) and approved
by the Bioethical Committee of the Universidad Mayor
and from Neurounion Biomedical Foundation (Protocol
CBA #05010).
Histology and immunostaining
Mice were sacrificed and perfused with PBS, and spinal
cords were collected. Spinal cords were fixed in parafor-
maldehyde (PFA, Merck, 30,525–89-4) 4% for 24 h and
then paraffin embedded. The spinal cords were sec-
tioned transversely in the lumbar section on a micro-
tome at 10 μm and were collected in positively charged
slides. Then, the slides were deparaffinized with xylol
and hydrated with descending concentrations of alcohol
until reaching distilled water. The epitopes were exposed
with citrate buffer at 96 °C for 40 min. After this, slides
were washed three times with 0.05% Tween20 in PBS.
The blocking of non-specific binding sites was done with
3% BSA in PBS solution for 40 min at room
temperature. Slides were incubated with primary anti-
bodies diluted in 1% BSA-0.05% Tween20 in PBS solu-
tion overnight at 4 °C. Primary antibodies and dilutions
were as follows: mouse anti-Pacer (custom-made from
Abmart), 1:100, rabbit anti-Rubicon (Invitrogen, PA5–
38017), 1:100, rabbit anti-GFAP (EMD Millipore Corp.,
AB5804), 1:1000, rabbit anti-NeuN (EMD Millipore
Corp., ABN78), 1:1000 and anti-MMP9 (Abcam,
ab38898). Secondary antibodies and dilutions were:
anti-mouse Alexa 555 (Thermo Fisher Scientific,
A28180), 1:1000 and anti-rabbit Alexa 488 (Thermo
Fisher Scientific, A27034), 1:1000 prepared in a 1%
BSA-0.05% Tween20 in PBS solution with DAPI (Invi-
trogen, D1306), 1:1000 or Hoechst (Life Technologies,
H3570), 1:1000 incubated for 2 h. Then, slides were
washed and mounted with Fluoromount-G (Invitrogen).
Images were taken with a Leica TCS SP8 confocal
microscope with a 10X, 40X and 63X objective magnifi-
cations. ImageJ and LAS X software were used to
process the stacked images.
Processing of human tissues
Frozen tissue was a generous gift from Dr. Robert H.
Brown, Jr. (University of Massachusetts Medical School).
Briefly, frozen post-mortem spinal cord tissue from
sALS patients and control subjects were obtained from
the Alzheimer Disease Research Center at Massachusetts
General Hospital and Dr. Robert H. Brown laboratory at
the Neurology Department of University of Massachu-
setts Medical School under approved Institutional Re-
view Board protocol (FWA#00004009). The biochemical
analysis of the human samples was also authorized by
the Ethics Committee of the Faculty of Medicine of the
University of Chile.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from mouse tissue (liver,
muscle, cortex, cerebellum, hippocampus, spinal cord)
by first homogenizing tissues in saline phosphate buffer
(100 μl of PBS, pH 7.4) with protease inhibitors (Thermo
Fisher Scientific, A32955 in a weight per volume ratio of
1:1. The same protocol was followed for post-mortem
human spinal cord samples preparation. 1 ml of TRIzol
LS (Invitrogen, 10,296,028) was added to 50 μl of hom-
ogenate. The remaining 50 μl were kept for Western blot
assays (see below). For RNA extraction from the mouse
motoneuron cell line NSC34 (Neuroblastoma Spinal
Cord 34) cells were pelleted, washed once with cold PBS
and directly resuspended in 700 μl of TRIzol LS. Total
RNA was isolated using the protocol recommended by
the manufacturer. cDNAs were synthesized using the
First Strand cDNA Synthesis Kit (Thermo Fisher Scien-
tific, K1621). qRT-PCR was carried out via SYBR Green
assays (Kappa biosystem, KK4601) using the Eco™
Real-Time PCR System (Illumina) according to the man-
ufacturer’s instructions. Each sample was run in tripli-
cates. mRNA expression was normalized to the 18 s
(cells) or actin (tissues) rRNA expression. Transcript
levels were quantified by using the ΔΔCt value method.
The following primers were used for quantitative
RT-PCR: Pacer forward 5′-TTCACCCACCAATCAAGA
GGGACA-3 and reverse 5′-ACAAGACTCTGCAG
ATGAGTGGCA-3′; Beclin1 forward 5′-CAGGAACTC
ACAGCTCCATTAC-3′ and reverse 5′-CCATCCTGG
CGAGTTTCAATA-3′; 18S forward 5′-GTAACCCGT
TGAACCCCATT-3′ and reverse 5′-CCATCCAAT
CGGTAGTAGGG-3′, Rubicon forward 5′- TTCAGCAT
CTCCGAGTCCTT-3′ and reverse 5′- AATCCCGTG
AACTGAACTGG-3′. For human samples, the primers
used were: hPacer forward 5′-ATGGTGTCACAATC
TACAGTCAGg-3′, reverse 5′-GGGAGAGGCAGCAT
CTGTC-3′; hRubicon forward 5′- CTGGCAGTT
CGTGAAAGACA -3′ and reverse 5′- TTAGCAGGA
AGGCAGCATCT-3′. β-actin forward 5′-AAGATCATT
GCTCCTCCTGA-3′ and reverse 5′-TACTCCTGC
TTGCTGATCCA-3′ primers were used for both mouse
and human samples. RT-PCR conditions were: 1 cycle at
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95 °C for 5 min, followed by 40 cycles at 95 °C for 30 s,
58 °C for 45 s.
Plasmid constructs
To generate the plasmid vector encoding mPacer-V5
mouse Pacer mRNA was extracted from C57BL/6 spinal
cord tissue and cloned into the pcDNA3.1/V5-His
TOPO vector (Invitrogen, 460,083). The PCR was car-
ried out in a final volume of 30 μl, containing 0.8 Units
of DreamTaq (Thermo Fisher Scientific, EP0701), 3 μl of
Dreamtaq Buffer (5x, Thermo Fisher, K1071), 0.6 μl of
dNTPs (10 μM) and 0.45 μl (10 μM) of each primer,
Pacer forward 5′- ATGAATTCAAGAGTCACGCCCAG
-3′ and reverse 5′-TGTTGCTGCAGTGGGCAA -3′.
PCR conditions were: 1 cycle at 95 °C for 5 min, followed
by 35 cycles at 95 °C for 30 s, 55 °C for 30 s, and 72 °C
for 2 min. The final extension step was carried out at 72
°C for 10 min. The PCR products were analyzed on 1%
agarose gel. The ligation of the PCR product into the
pcDNA3.1/V5-His TOPO vector was performed ac-
cording to the manufacturer’s recommendation. The
resulting pcDNA3.1/mPacer-V5-His plasmid was amp-
lified in E. coli DH5α, and the correct insertion of the
Pacer gene was verified by sequencing. The vector en-
coding hPacer-V5 was designed using the Vector-
Builder online tool (Cyagen) and subsequently
completely synthesized by and purchased from Cya-
gen. Plasmid for FLAG-tagged Beclin1 were kindly
provided by Beth Levine [40].
Cell culture, transfection, and viral transduction
We used HEK293T cells for immunoprecipitation assays
and the NSC34 cell line as a motoneuron-cell like a
model [41] for autophagy experiments, subcellular
localization studies and mutant SOD1 aggregation and
cell death analysis. NSC34 and HEK 293 T cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM,
Gibco, 12,800,017) supplemented with 10% fetal bovine
serum (FBS, Gibco, 10,438,026) and 1% penicillin/
streptomycin (Biological Industries, DW1012), in a 5%
CO2 incubator at 37 °C. All transfections were per-
formed using the Effectene reagent (Qiagen, 301,427) ac-
cording to the manufacturer’s recommendations.
Plasmid DNAs were prepared using the Qiagen plasmid
midi kit (Qiagen, 12,143) or the Axygen miniprep kit
(Axygen, AP-MN-P-250). For viral transductions, lenti-
virus production was performed with Lenti-vpak (Ori-
gene, TR30037), according to the manufacturer’s
recommendation. Briefly, HEK293T cells were trans-
fected with scramble control (shCtrl) and shPacer con-
structs. Medium was replaced with fresh DMEM after
12 h, and viral supernatant was collected after 36 h and
again after another 24 h. NSC34 cells were transduced
with 2 ml viral supernatant. Stable NSC34 shCtrl and
shPacer cell lines were established with Puromycin
(Sigma, P8833-25 mg) (10 μg/ml) selection.
Autophagy analysis
NSC34 cells were transfected with vectors encoding
mouse Pacer-V5 or empty vector (pcDNA3.1/V5) (Invi-
trogen) or with vectors targeting mouse Pacer mRNA,
shPacer A (GGACACAGAAGACGCCAGCAGGTT
ACGTG), shPacer B (TGGTACAACGGCCATTGGA
GAGCTGTGTT) or a scramble control vector (shCtrl)
(OriGene). To induce autophagy cells were treated with
rapamycin (200 nM, Enzo Life Sciences, BML-A275) for
6 h. For the autophagy flux, cells were washed once with
PBS and maintained with EBSS (Gibco, 24,010,043)
medium for 0.5, 2, or 4 h. To inhibit
autophagosome-lysosome fusion, cells were treated with
a mix of bafilomycin A1 (0.5 μM), and protease inhibi-
tors pepstatin (10 μg/ml), and E64D (10 μg/ml) for 4 h,
all purchased from Merck.
Immunofluorescence assay
NSC34 cells were seeded on coverslips and grown over-
night. Briefly, cells were transfected and after 24 h cells
washed in PBS, fixed with 4% paraformaldehyde (Merck)
for 10 min at room temperature, permeabilized with
0.1% Triton X-100 (Merck, 9036-19-5) and 5% gelatin
from cold water fish (Sigma, 9000-70-8) for 2 h at room
temperature in a moisture chamber. Antibodies and
concentrations employed were: mouse Pacer (custom--
made from Abmart), 1:100; rabbit anti-Beclin1 (Santa
Cruz Biotechnology, sc-11,427), 1:100. Secondary anti-
bodies were used as follows: anti-mouse Alexa 555
(Thermo Fisher Scientific, A28180), 1:1000 and
anti-rabbit Alexa 488 (Thermo Fisher Scientific,
A27034), 1:1000. Nuclei were stained with Hoechst
33342 (Life Technologies, H3570)1:1000. Coverslips
were mounted with Fluoromount G. Fixed cells were im-
aged with a Leica TCS SP8 confocal microscope. ImageJ
and LAS X were employed to process the stacked
images. The co-localization analysis was performed as in
[42]. Briefly, confocal images were processed using CDA
software. Applying the same thresholds for all experi-
mental conditions, the software provides a coefficient of
colocalization (Pearson’s correlation coefficient), which
was used comparatively.
Immunoprecipitation assay
HEK293T cells were co-transfected with vectors encod-
ing mouse Pacer-V5 and Flag-tagged Beclin1. 48 h later,
cell extracts were collected, centrifuged and resuspended
in 500 μl of lysis buffer (0.2% NP40, 100 mM KCl, 50
mM Tris at pH 7.5, 150 mM NaCl, 250 mM PMSF) con-
taining protease inhibitor cocktail 1 X (Thermo Fisher
Scientific, A32955). After incubation overnight on ice,
Beltran et al. Molecular Neurodegeneration           (2019) 14:14 Page 4 of 18
total cell extracts were subjected to immunoprecipita-
tion (IP) with anti-V5 antibody conjugated-agarose beads
(MBL International, 3315) for 2 h at 4 °C on a wheel
rotor. Subsequently, beads were washed twice with lysis
buffer and once with lysis buffer containing 500 mM
NaCl. Protein complexes were eluted with V5 peptide.
The input and IP eluate were separated by SDS-PAGE
and assessed by Western blot analysis.
Western blot analysis
Cells and tissues were homogenized in Triton buffer
(1.0% Triton in PBS) containing protease inhibitor cock-
tail 1X by sonication. Protein concentration was deter-
mined by BCA assay (Pierce Thermo Fisher Scientific,
23,225). Antibody and dilutions used were: mouse
anti-human-Pacer (Novus, B01P), 1:1000, rabbit
anti-Rubicon (Cell Signaling, 8465), 1:1000, rabbit
anti-LC3B (Cell Signaling Technology, 2575), 1:1000,
mouse anti-SQSTM1/p62 (Abcam, ab56416), 1:10000,
mouse anti-V5 (Thermo Fisher Scientific, R960-CUS),
1:4000, rabbit anti-Beclin1 (Santa Cruz Biotechnology,
sc-11,427),1:1000, mouse anti-GFP (Santa Cruz Biotech-
nology, sc-9996), 1:2000, sheep anti-SOD1 (Calbiochem,
574,597), 1:1000, and custom mouse anti-Pacer antibody
manufactured by Abmart raised against a 14 aa peptide
of the N-terminal domain of mouse Pacer, 1:1000. Rabbit
anti-HSP90 (Santa Cruz Biotechnologies, sc-7947) or
rabbit anti-β-Actin (Cell Signaling Technology, 4967)
were used as loading controls, 1:3000 or 1:1000, respect-
ively. Secondary HRP-conjugated anti-rabbit (Life Tech-
nologies, 656,120), anti-mouse (Life Technologies,
626,520) or anti-sheep (Sigma-Aldrich, A3415) anti-
bodies were employed at a 1:3000 dilution.
Analysis of SOD1 aggregation
NSC34 cells were transiently transfected with the SOD1
expression constructs (SOD1WT and SOD1G93A) fused to
EGFP. To verify the SOD1 aggregate formation, we
employed three assays: (i) Insolubility in non-denaturing
detergents of SOD1 species was assessed by Western
blot analysis. After 48 h of transfection, total cell extracts
were prepared in 1% Triton buffer in PBS, according to
the Western blot protocol described above. The samples
were treated with or without reducing agent 100 mM di-
thiothreitol (DTT) (Thermo Fisher Scientific, R0861).
(ii) SOD1 aggregate formation was verified by filter trap
assay as detailed in [43]. Briefly, 1 μg/μl protein NSC34
cell extracts treated with or without DTT were filtrated
through a 0.2 μm cellulose acetate membrane by using a
BRL dot-blot filtration unit. SOD1 aggregates were de-
tected with anti-SOD1 antibody, following the immuno-
logical protocol described above. (iii) SOD1 inclusions
were monitored by confocal microscopy. In brief,
NSC34 cells were seeded on coverslips, transfected with
corresponding vectors. After 48 h cells were fixed with
4% paraformaldehyde in PBS for 20 min at room
temperature. Fixed cells were imaged with a Leica TCS
SP8 confocal microscope with a 40X objective magnifi-
cation. ImageJ and LAS X were employed to quantify
EGFP-positive cells with inclusions and to process the
stacked images. (iv) For the isolation of detergent-insoluble
protein aggregates, NSC34 cells were seeded in 6-well
plates. After 24 h cells were transiently transfected with the
SOD1 expression constructs (SOD1WT and SOD1G93A)
fused to EGFP together with shCtrl or shPacer and
hPacer-V5. After 48 h of transfection, the cells were col-
lected and centrifuged at 4 °C for 5min at 900×g the cell
pellet was re-suspended with 200 μl buffer TEN (10mM
Tris-HCl, 1mM EDTA, 10mM NaCl, pH 8.0) buffer, con-
taining protease inhibitor cocktail 1 X (Thermo Fisher Sci-
entific, A32955) supplemented with 0.5% of non-ionic
detergent Nonidet P-40 (NP-40) (EMD Millipore Corp.,
9016-45-9), the samples were sonicated 10 s on ice, 40 μl
from the total lysate was saved as Input. The remaining lys-
ate was cleared by centrifugation at 800×g for 10min at 4 °
C. To separate the soluble protein fraction and the
detergent-insoluble protein aggregates the supernatant was
then submitted to centrifugation at 16900×g for 45min at
4 °C, [44]. The pellet containing the aggregates was washed
by addition of TEN buffer and centrifuged again at
16900×g for 45min at 4 °C. The washed pellet was solubi-
lized in TEN buffer containing 0.5% SDS and protease in-
hibitor cocktail followed by Western blot analysis under
reducing conditions.
Cell death assay
NSC34 cells stably transduced with shPacer and shCtrl
constructs and then transfected with EGFP, SOD1WT,
SOD1G93A, and hPacer-V5, after 48 h and 72 h the cells
were collected and stained with 250 nM of SytoxBLue™
(Thermo Fisher Scientific, S34857). SytoxBlue™ positive
cells were monitored by Flow cytometry using a BD
FACSVerse™ flow cytometer. FlowJo software version
7.6.1. was used to analyze data.
Statistical analysis
GraphPad Prism software was used for statistical ana-
lysis. All data were analyzed by one-way ANOVA or Stu-
dent’s t-test. N indicates the number of biological
replicates. On all graphs, error bars represent SEM.
Results
ALS network analysis links C13orf18/Pacer to autophagy
We used a convergent network analysis approach based
on [26] to integrate ALS specific high-throughput data,
such as HUGE phenopedia and copy number variation
(CNV) data (Additional file 1: Table S1) [33–36], with
the global protein-protein interaction network. This
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approach allowed us to build interaction networks with
all ALS associated genes, thus uncovering new connec-
tions to previously unrecognized genes/proteins as being
part of the ALS disease network (Fig. 1a; Additional file 3:
Figure S1 and Additional file 2: Table S2). An evidence-
based output of 241 genes/proteins organized in 12
ALS-specific subnetworks was obtained (Additional
file 3: Figure S1 and Additional file 2: Table S2). We
selected Pacer (C13orf18) for further experimental
studies, mainly because it was displayed as a compo-
nent of a subnetwork composed of itself and Beclin1
(Fig. 1a and Additional file 3: Figure S1h), an inter-
action previously reported in a proteomic study [30].
Beclin1 is a well-characterized core subunit of distinct
phosphatidylinositol 3 kinase (PI3K) complexes, which
mediate multiple steps during the autophagy process.
A role for Beclin1 had been implicated in ALS path-
ology since its levels were found to be increased in the
spinal cord from ALS mouse models, as well as in
postmortem sALS spinal cord samples [22, 45, 46].
Through its interaction with Beclin1, Pacer was sug-
gested to functionally connect to the autophagy
process [30], which recently was further confirmed by
two studies that reported the interaction of Pacer with
several components of the Beclin1 complex, including
Beclin1, UVRAG, PI3KR4 and PI3KC3 [32, 47]. Hence,
we hypothesized that Pacer could play a regulatory
role in the autophagy pathway through interaction
with Beclin1 and affect ALS pathology through this
pathway. Furthermore, an SNP discovered in the
3’UTR of Pacer in a cohort of ALS patients suggests
that it could be a modifier of disease [31].
No functional commercial antibody was available to
detect mouse Pacer. Hence an antibody targeting en-
dogenous mouse Pacer was custom-made for this
study by Abmart. Initially, eight peptides unique to
the mouse sequence were tested; however, only pep-
tide 43-SWINPLCVQQPLQE-57 generated an anti-
body that detected one band at the expected size of
72 kDa in the mouse motoneuron cell line NSC34 by
Western blot (Fig. 1b and c). Specificity of the anti-
body was confirmed by knockdown of mouse Pacer
using two shRNA constructs targeting its expression
(Fig. 1c and Additional file 4: Figure S2a). The ex-
pression level of many autophagy genes, e.g., Beclin1,
is generally upregulated upon activation of this path-
way [48]. We assessed the possible regulation of Pacer
expression under autophagy induction in NSC34 cells.
Pacer endogenous mRNA and protein levels were in-
creased after treatment with rapamycin, similar to
Beclin1 mRNA and protein levels (Fig. 1d and e) as
well as LC3B-II protein levels (Fig. 1e). To confirm
the interaction of Pacer with Beclin1, we used
V5-tagged mouse Pacer (Pacer-V5) in HEK293T cells
and performed immunoprecipitation (IP) experiments.
Using the V5-tag on Pacer, we observed that en-
dogenous Beclin1 is found in protein complexes with
Pacer-V5 (Fig. 1f ). By using the custom-made Pacer
antibody, we confirmed endogenous Pacer/Beclin1
colocalization in NSC34 cells (Fig. 1g). The Pearson’s
correlation coefficient between the two proteins was
found to increase from 0.26 under basal conditions to
0.53 under autophagy activation with rapamycin (Fig.
1h).
To investigate the presence of Pacer mRNA in tissues
relevant to ALS pathogenesis, we assessed Pacer,
Rubicon and Beclin1 mRNA levels by quantitative PCR
in different mouse tissues (cortex, cerebellum, hippo-
campus, spinal cord, muscle, and liver) obtained from
100 days-old wild-type C57BL/6 mice (4 males and 4 fe-
males). The three genes displayed elevated mRNA ex-
pression in the central nervous system (CNS) when
compared to muscle or liver (Additional file 4: Figure
S2b). Pacer and Rubicon showed higher expression in
the spinal cord and cortex, while Beclin1 expression was
elevated in the hippocampus, confirming previous find-
ings (Additional file 4: Figure S2b) [49].
The same antibody described above was subsequently
used to detect endogenous mouse Pacer in mouse spinal
cord tissue. In the lumbar spinal cord of 60 days old
wild-type mice, Pacer cell-type expression was investi-
gated by immunofluorescent staining and confocal mi-
croscopy. Strikingly, Pacer appeared to be expressed
mainly in neurons in the spinal cord, with no obvious
detection in astrocytes (Additional file 4: Figure S2c).
Pacer levels are decreased in ALS pathology
We next evaluated possible alterations in Pacer levels in
human postmortem spinal cord samples derived from
patients with sALS compared to non-ALS patients (Add-
itional file 5: Table S3). We found a significant decrease
in Pacer protein levels in the lumbar spinal cord of sALS
patients compared to age-matched healthy control sub-
jects (Fig. 2a). A similar trend was observed in the thor-
acic spinal cord, yet no tendency was found in the
cervical spinal cord (Fig. 2a). However, for both cervical
and thoracic sections tissues from only two control cases
were available. Interestingly, in sALS patients the de-
crease of Pacer protein levels correlated with the in-
crease of Rubicon protein levels in the same patient, a
phenomenon observed in all spinal cord sections (Fig. 2a).
While Pacer mRNA levels were not altered, Rubicon
mRNA levels were increased in the lumbar spinal cord of
sALS patients (Additional file 6: Figure S3a and b). These
findings indicate that at least the lumbar region of the
spinal cord of sALS patients displays a significant loss of
Pacer protein levels, suggesting a possible involvement of
Pacer in ALS pathogenesis.
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We then evaluated Pacer levels in tissue derived from
two ALS mouse models, TDP43A315T and SOD1G93A
transgenic mice (TDP43A315T-Tg and SOD1G93A-Tg, re-
spectively) [37, 38, 50]. We assessed Pacer mRNA and
protein levels in the lumbar spinal cords of late symp-
tomatic transgenic mice compared to their respective
non-transgenic (non-Tg) littermates in the age range of
159 to 189 days for TDP43A315T-Tg mice and 131 to 152
days for SOD1G93A-Tg mice. Pacer protein levels were
significantly diminished in the spinal cords of symptom-
atic TDP43A315T-Tg and SOD1G93A-Tg mice compared
to their respective non-Tg controls (Fig. 2b and c). In
comparison, Rubicon protein levels were not affected in
either mouse model (Fig. 2b and c). Both Pacer and Ru-
bicon mRNA levels were not altered in either mouse
model (Additional file 6: Figure S3c and S3d).
To investigate if the localization of Pacer to neurons is
affected under disease condition, we performed im-
munofluorescence staining and confocal microscopy of
lumbar spinal cord sections of symptomatic SOD1-
G93A-Tg mice and their age-matched littermate controls
(in the age range from 138 to 156 days). We focused on
the ventral horn region of the spinal cord where moto-
neurons are found. In non-Tg animals, Pacer localized
mainly to neurons, including motoneurons in the ventral
horn (Fig. 3a and b, upper panels). In symptomatic
SOD1G93A-Tg mice less overall Pacer staining in neurons
was found, possibly due to a lower number of surviving
neurons in the ventral horn of the spinal cord (Fig. 3a
and b, lower panels). Surprisingly, in SOD1G93A-Tg mice
Pacer also localized to astrocytes, which was not ob-
served in non-Tg control mice (Fig. 3b, lower panel).
Like Pacer, Rubicon was also preferentially expressed in
neurons, in non-Tg control mice (Fig. 3c and d, upper
panels). Similar to Pacer, Rubicon staining was dimin-
ished in neurons in symptomatic SOD1G93A-Tg mice
possibly due to a motoneuronal loss in the ventral horn
of the spinal cord (Fig. 3c and d, lower panels).
To assess if the decrease in Pacer levels under disease
conditions is simply due to the loss of motoneurons in
the symptomatic spinal cord or if Pacer levels are af-
fected already earlier, we evaluated Pacer levels also in
pre-symptomatic SOD1G93A-Tg and age-matched
non-Tg mice (60 days). Pacer levels were reduced in
pre-symptomatic SOD1G93A-Tg, similar to Rubicon,
Beclin1 and LC3-II (Additional file 7: Figure S4a), which
could be due to the activation of the autophagy pathway.
Additionally, the localization of Pacer in the spinal cord
of pre-symptomatic SOD1G93A-Tg and age-matched
non-Tg mice (60 days) was investigated. Pacer was found
to localize mainly to neurons in both Tg and non-Tg ani-
mals (Additional file 7: Figure S4b and S4c). No staining
was observed in astrocytes in pre-symptomatic mice
(Additional file 7: Figure S4c). Similar as reported in [21,
51], we used metalloproteinase-9 (MMP9) as a marker
for vulnerable neurons known to degenerate in ALS
mouse models. Pacer was found to localize to
MMP9-positive neurons in both SOD1G93A-Tg and
non-Tg mice (Additional File 8: Fig. S5a and S5b), never-
theless, in SOD1G93A-Tg mice, the immunofluorescence
labeling of Pacer appeared to be decreased compared to
non-Tg mice (Additional file 8: Figure S5b). Together
with our results in Western blot, these data suggest that
vulnerable neurons display a decrease in Pacer expres-
sion already at presymptomatic stages in the SOD1G93A
ALS mouse model.
Diminished Pacer levels impair autophagy
Since Pacer was indicated by our network analysis to
associate with Beclin1 and its levels were decreased
in ALS-affected tissue, we assessed the possible role
of Pacer expression in autophagy using a
loss-of-function approach. To determine if the loss
of Pacer affects the autophagy process, we monitored
autophagy flux in NSC34 cells deficient for Pacer.
We depleted Pacer in NSC34 cells using
short-hairpin RNAs (shPacer A and B) (Fig. 1c and
Additional file 4: Figure S2a) and determined the
levels of key autophagy markers in NSC34 cells
under serum deprivation conditions (EBSS) in the
(See figure on previous page.)
Fig. 1 Pacer is identified as a protein involved in autophagy in the context of an ALS disease network. a Scheme for the convergent analysis
performed for ALS data. CNV, copy number variation; IPA, Ingenuity pathway analysis. b Scheme of localization of a total of 8 peptides (dark gray
boxes) used to generate an antibody specific for mouse Pacer. Only one peptide (pink box) resulted in the generation of a specific antibody. The
aa sequence of this peptide is shown. c, The specificity of the antibody generated in b was tested by depleting NSC34 cells of Pacer expression
using two shRNA constructs targeting mouse Pacer mRNA (shPacer A and shPacer B). As a mock control, a scrambled shRNA (shCtrl) construct
was used. Pacer was detected by a custom-made antibody by Western blot, a non-transfected (NT) is shown. A representative of 3 independent
experiments is shown. d, e NSC34 cells were treated with rapamycin for 6 h. d mRNA extraction and quantitative PCR was performed (n = 4). e,
Extracts of NSC34 cells were subjected to Western blot analysis. Protein levels of Pacer, Beclin1, and LC3-II were verified. β-Actin serves as a
loading control. f IP was performed with extracts from HEK293T cells transfected with expression vector for mouse Pacer-V5 or empty control
vector for 48 h. IP was performed using the V5 tag. The interaction of V5-tagged Pacer with endogenous Beclin1 was analyzed by Western blot.
The inputs and elutions are shown. g, h The colocalization of endogenous Pacer and Beclin1 in NSC34 cells under basal (NT) and Rapamycin
(Rapa) treatment was was analyzed by g, confocal microscopy and h, quantified using Pearson’s coefficient (n = 3). The nuclei are visualized with
Hoechst. Mean and SEM with only statistical significant p-values are shown: *, p ≤ 0.05
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presence or absence of lysosomal inhibitors. Deple-
tion of Pacer decreased LC3-II flux in NSC34 cells
(Fig. 4a and b), suggesting an impairment of the au-
tophagy process. Autophagy substrate p62 and
Beclin1 were not significantly affected (Fig. 4a and
Additional file 9: Figure S6a and S6b). Taken to-
gether, our results suggest that reduced levels of
Pacer negatively affect the autophagy pathway.
Pacer repression promotes SOD1 aggregate accumulation
and triggers cell death
To determine the consequences of reduced Pacer levels in
the ALS pathogenesis which we observed in vivo (Fig. 2),
we assessed the impact of its repression on mutant SOD1
aggregation and neuronal cell death. Knocking down Pacer
in NSC34 cells led to increased mutant SOD1
disulfide-dependent aggregation (Fig. 4c). Interestingly, we
also observed the spontaneous aggregation of wild-type
SOD1 upon loss of Pacer (Fig. 4c), a phenomenon de-
scribed in sALS cases [52–54]. Similar results were ob-
tained by determining the levels of Nonidet P-40 (NP-40)
detergent-insoluble protein aggregates (Additional file 9:
Figure S6c), as well as by filter trap, an assay that detects
protein aggregates by size using a cellulose acetate filter
membrane with 200 nm pores (Fig. 4d). Since our shRNA
constructs target mouse Pacer exclusively, we restored
Pacer levels by exogenous expression of human Pacer (hPa-
cer-V5) (Additional file 9: Figure S6d and S6e). The
re-expression of hPacer-V5 restored SOD1 aggregation
levels to a similar extent to those observed in control cells
(Fig. 4c, d and Additional file 9: Figure S6c). Furthermore,
confocal microscopy of SOD1 confirmed these findings.
Depletion of Pacer in NSC34 cells led to an increased num-
ber of inclusions formed by SOD1G93A (Fig. 4e and
Additional file 10: Figure S7), whereas it had dramatic ef-
fects on SOD1WT, which built large de novo inclusions
similar in size to aggregates observed for mutant SOD1
(Fig. 4e and Additional file 10: Fig. S7). No effect of Pacer
depletion on EGFP alone was observed (Fig. 4e and
Additional file 10: Figure S7). Since impaired autophagy
and increased protein aggregation are correlated with neur-
onal death, we investigated the effect of knocking down
Pacer in NSC34 cells expressing wild-type or mutant
SOD1. We found that the depletion of Pacer sensitizes cells
to SOD1WT or SOD1G93A toxicity, whereas cells expressing
EGFP alone are unaffected (Fig. 4f and Additional file 10:
Figure S7a and S7b). In comparison, the depletion of Rubi-
con did not result in cell death in NSC34 cells expressing
mutant SOD1 (Additional file 10: Figure S7c and S7d). Fur-
thermore, the reconstitution with hPacer-V5 rescued the
survival of cells expressing SOD1WT or SOD1G93A (Fig. 4f).
Human Pacer expression even improved the survival rate
when compared to cells expressing scrambled shRNA con-
struct (shCtrl cells) in the presence of SOD1G93A (Fig. 4f).
Taken together these results indicate an important role for
Pacer in maintaining proteostasis in motoneurons by pro-
moting SOD1 aggregate removal and sustaining moto-
neuron survival.
Discussion
Neurodegenerative diseases, such as AD, PD, and ALS,
are multifactorial, involving a combination of genetic
and environmental factors, as well as age as the primary
risk factor. Genetic studies in ALS have made significant
advances in the understanding of disease pathogenesis
by using whole genome or whole exome sequencing
strategies (reviewed in [2]). However, the primary cause
of approximately half of fALS cases and the majority of
sALS cases remains unexplained. The use of systems
biology approaches to study neurodevelopmental and
neurodegenerative diseases has recently proven to aid
our understanding of underlying disease mechanisms by
unraveling new genes, pathways or subnetworks respon-
sible for an illness which would not have been recog-
nized using traditional approaches. Here we describe
Pacer, a protein previously proposed as a tumor suppres-
sor and cancer biomarker [55–57] and recently reported
to be associated with autophagy [32], as being immersed
in the ALS disease network. We performed a convergent
analysis by merging all ALS data available to uncover
(See figure on previous page.)
Fig. 2 Pacer levels are reduced during ALS pathology. a Human Pacer (hPacer) and human Rubicon (hRubicon) protein levels were determined
in post-mortem spinal cord sections from sALS patients and age-matched control subjects. Left panel, cervical spinal cord section with Controls
n = 2 and sALS patients n = 6; middle panel, thoracic spinal cord section with Controls n = 2 and sALS patients n = 7; and right panel, lumbar
spinal cord section with Controls n = 6 and sALS patients n = 7. β-Actin serves as a loading control. Densitometric quantifications of hPacer and
hRubicon normalized to β-Actin levels are shown. b Pacer and Rubicon protein levels were determined in lumbar spinal cord samples of late
symptomatic TDP43A315T transgenic mice (TDP43A315T-Tg, n = 5) and their non-transgenic littermate controls (n = 3), respectively. TDP43
aggregate levels under non-reducing (−DTT) conditions are shown as positive controls. β-Actin serves as a loading control. Densitometric
quantifications of Pacer protein levels normalized to β-Actin levels are shown. c, Pacer and Rubicon protein levels were determined in the lumbar
spinal cord of late symptomatic SOD1G93A transgenic mice (SOD1G93A-Tg) and their non-transgenic littermate controls (both groups n = 7). p62
protein levels were detected as a positive control of impaired autophagy. SOD1 aggregate levels under non-reduced (−DTT) conditions are
shown as a positive control for SOD1G93A-Tg mice. β-Actin serves as a loading control. Densitometric quantifications of Pacer protein levels
normalized to β-Actin levels are shown. In a-c Statistical analyses were performed using Student’s t-test. Mean and SEM with only statistical
significant p-values are shown: *, p ≤ 0.05; **, p ≤ 0.01; and ***, p ≤ 0.001
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pathways and associated new genes involved in the dis-
ease. By retrieving and integrating data from different
model systems and patient studies, experimental bias
was filtered out, and only relevant mechanisms may be
uncovered. From the list of genes obtained through this
analysis, we selected the protein Pacer, previously known
as C13orf18, based on its putative role in autophagy, a
compromised pathway during ALS pathogenesis. At the
time, the only data available for Pacer was based on a
proteomic study of the autophagy network, which sug-
gested a role in the autophagy pathway via interaction
with Beclin1 [30]. Furthermore, a connection to ALS
was suggested by the identification of an SNP in the
3’UTR of the Pacer gene in a cohort of sALS patients
[31]. The specific consequence of the SNP in the 3’UTR
of the Pacer gene in ALS pathogenesis, however, need to
be more explored in future studies. The likely presence
of variants in the UTR or intronic regions of ALS genes
has been exemplified by the most common genetic
modification known to cause ALS, C9orf72 intronic rep-
etitions [58]. Furthermore, variants in untranslated re-
gions of well-known ALS-causing genes, including
SOD1, TARDBP, FUS and UBQLN2, have been recently
reported [59]. Although these variants do affect the
amino acid sequence of the affected the protein, they
can have important effects on other aspects, such as ex-
pression level. For instance, Al-Chalabi and co-workers
showed that variants in the 3’UTR of the FUS gene
found in Italian ALS patients promote mislocalization of
the FUS protein and result in a dramatically increased
expression of this protein [60, 61]. Similarly, variants
found in the 3’UTR of the TARDBP gene also regulate
its expression by affecting the RNA stability of its tran-
scripts [62]. Here, we found Pacer levels to be decreased
in sALS patients, similarly to two fALS mouse models,
hence Pacer may participate in a transversal mechanism
to protect neurons against disease.
Recently, Pacer was described as a positive regulator of
autophagosome maturation, through its binding to the
functionally distinct UVRAG-Beclin1-Vsp34 and
UVRAG-HOPS complexes [32]. Pacer is proposed to
target both protein complexes to the autophagosome
membrane for activation [32]. Beclin1 is a core subunit
of distinct PI3K complexes, which mediate multiple
steps during the autophagy process. Beclin1 levels were
found to be increased in the spinal cord from ALS
mouse models, as well as in postmortem sALS spinal
cord samples [22, 45, 46]. We have shown that
haploinsufficiency of Beclin1 in a mutant SOD1 mouse
model increases the lifespan of double-transgenic mice,
despite the increase in SOD1 aggregates [22], consistent
with recent findings in Atg7 deficient animals [21]. In
another study, however, targeting Beclin1 in two differ-
ent mouse models of ALS showed opposite results [46].
Here, we show that Pacer is expressed in the CNS, par-
ticularly in neurons in the spinal cord, suggesting it to
have an essential role in neuronal cells in this tissue. We
show that Pacer levels are decreased in the lumbar re-
gion of the spinal cord in two fALS mouse models in the
late stage of the disease and biopsies of sALS patients.
Furthermore, we found that while Pacer protein levels
decrease in the late stage of disease in both mice and
humans, Rubicon protein levels are maintained in mice
or increased in humans. In histological studies, we found
that in late symptomatic SOD1G93A transgenic mice the
Pacer staining was diminished in motoneurons, probably
due to the loss of motoneurons, whereas its expression
was augmented in astrocytes. Progressive reactive astro-
gliosis is a feature of the ALS pathogenesis, mainly
found surrounding degenerating neurons [63]. Changes
in the expression of autophagy proteins specifically in
astrocytes during ALS have not been reported to our
knowledge. Our finding that Pacer is also expressed in
astrocytes in the symptomatic stage of an ALS mouse
model whereas it is only found in neurons in the pre-
symptomatic stage could imply a role of Pacer in the in-
flammatory response of the astrocytes during disease
progression, however further investigastions are neces-
saries to clarify this point.
Similar to Pacer, Rubicon also was localized primarily
to neurons in the lumbar spinal cord in non-Tg mice.
Nevertheless, in late symptomatic SOD1G93A-Tg animals
Rubicon localization to motoneurons was diminished
similarly to Pacer. However, its expression was aug-
mented in another cell type, other than astrocytes, pos-
sibly microglia, which remains to be investigated further.
Hence, our results suggest that the expression of both
Pacer and Rubicon is highly dynamic and can change de-
pending on the cell type as well as under ALS disease
condition. Additionally, our results raise caution for the
interpretation of Western blot results which represent
overall protein levels and cannot distinguish changes of
expression in various cell types, such we have observed
in our histological analysis for both Pacer and Rubicon.
To investigate whether the loss of Pacer during the
late stage of disease signifies a possible involvement in
(See figure on previous page.)
Fig. 3 Pacer and Rubicon localization in the spinal cord of symptomatic SOD1G93A transgenic mice. Confocal microscopy of lumbar spinal cord
sections of late symptomatic (138 to 156 days old) SOD1G93A transgenic mice (SOD1G93A-Tg) compared to age-matched non-transgenic controls
(non-Tg). Z-stack of confocal images, detection of Pacer, the neuronal marker NeuN in a, or the astrocytic marker GFAP in b, detection of
Rubicon, the neuronal marker NeuN in c, or the astrocytic marker GFAP in d. a-d, Nuclei are stained with DAPI. Scale bar: 20 μm
Beltran et al. Molecular Neurodegeneration           (2019) 14:14 Page 12 of 18
a
c
d
e
f
b
Fig. 4 (See legend on next page.)
Beltran et al. Molecular Neurodegeneration           (2019) 14:14 Page 13 of 18
ALS pathogenesis or is only representative of the loss of
vulnerable neurons during the course of the disease, we
also determined its levels and localization during the
presymptomatic stage of the disease at age 60 days in the
SOD1G93A mouse model. We found that total Pacer
levels are already significantly decreased in presymptom-
atic SOD1G93A-Tg mice, while we do not observe any
neuronal loss or signs of astrogliosis, as has been re-
ported [64]. In the presymptomatic stage, Pacer appears
to be expressed exclusively in neurons in the lumbar
spinal cord in SOD1G93A-Tg mice, comparable to
non-Tg littermate controls, nevertheless its overall signal
seemed reduced in transgenic mice, possibly reflecting
its decreased total protein level observed in Western
blot. To show that Pacer localizes to the neurons that
are lost later during disease progression, we performed
co-staining of Pacer with MMP9, a marker for vulner-
able motoneurons [21, 51]. Indeed, we found that Pacer
colocalizes with MMP9, hence our data suggests a cor-
relation between the loss of function of Pacer in spinal
cord motoneurons and ALS pathogenesis.
To study the role of Pacer during ALS pathogenesis,
we used the mouse motoneuron-like cell line NSC34.
We demonstrated that Pacer expression is up-regulated
on the transcriptional and translational level upon au-
tophagy induction, resembling the behavior of other au-
tophagy genes [65, 66]. Furthermore, we confirmed the
interaction between Pacer and Beclin1. Comparable re-
sults were obtained by Cheng et al. in U2OS cells re-
cently [32]. Pacer shares highest sequence homology
with Rubicon, which has become, in recent years, known
as an important regulatory protein of autophagy and
endocytosis, as well as of LC3-associated phagocytosis
[67–71]. Pacer and Rubicon are part of the same protein
family due to their shared Rubicon homology (RH) do-
main. Interestingly, they were reported to perform op-
posing functions in the autophagy pathway, Rubicon as
a negative regulator of the UVRAG-Beclin1-Vsp34 and
UVRAG-HOPS complexes through its binding to
UVRAG, while Pacer antagonizes Rubicon by competing
for UVRAG binding, hence positively influencing
autophagy activity [32]. In concordance with these re-
sults obtained in HEK293T cells [32], we also find that
motoneurons depleted of Pacer are impaired in their au-
tophagy flux.
In the current literature, the dependence of motoneu-
rons and the neuromuscular junction (NMJ) on autoph-
agic activity is actively discussed [21, 72, 73]. On one
hand due to the importance of autophagy in maintaining
the high metabolic rate of motoneurons and on the
other hand the requirement of motoneuron autophagy
in preserving neuromuscular innervation [21]. Motoneu-
rons have been shown to be extremely dependent on an
efficient autophagy flux, referring to an accurate degrad-
ation of the formed autophagosomes in the lysosome
[21, 72]. Furthermore, during aging a progressive impair-
ment of late endolysosomal processes is observed in
neurons, resulting in increased cellular stress owing to
the continuous input of new autophagosomes to cope
with the turnover of organelles and other cargos
(reviewed in [74, 75]). In ALS a progressive decrease in
autophagic/endocytic activity in affected motoneurons
has been described in fALS mouse models since early
stages of the disease [76, 77]. In sALS patients, the levels
of autophagy markers in spinal cord postmortem sam-
ples were described to be increased, including levels of
Beclin1, LC3-II and the autophagy-substrates p62, pro-
tein aggregates, and unfunctional organelles, correlating
with a dysregulation of the pathway [45, 46]. Finally, mu-
tations in several autophagy-related genes were found
associated with fALS, further supporting the notion that
autophagy dysfunction is a significant pathogenic mech-
anism of disease (reviewed in [8]). In our study, we
found that Pacer loss of function in a motoneuron cell
line results in an augmentation of mutant SOD1 aggre-
gation, as well as an unexpectedly drastic de novo aggre-
gation of wild-type SOD1. This phenomenon may be
explained by the disruption of the autophagy process
due to loss of Pacer since both wild-type and mutant
SOD1 are autophagy substrates [78]. Together these re-
sults suggest that Pacer is required for protein aggregate
degradation under physiologic and disease conditions
(See figure on previous page.)
Fig. 4 Depletion of Pacer impairs autophagosome formation and promotes SOD1 aggregation. a Autophagy flux under Pacer knockdown. Cells
were treated with EBSS medium or/and lysosome inhibitors (Lys. Inh.) for 0.5, 2 and 4 h. Cell extracts were subjected to Western blot. As a mock
control, a scrambled shRNA (shCtrl) construct was used. Pacer, Beclin1, p62 and LC3-II formation levels were determined. β-Actin serves as a
loading control. b Densitometric quantifications of LC3-II flux (n = 3). One-way ANOVA and Bonferroni’s post hoc tests were performed.Mean and
SEM with only statistically significant p-values are shown: *, p ≤ 0.05. c-f, NSC34 cells depleted of Pacer were transiently co-transfected with
expression vectors for human wild-type or mutant SOD1G93A fused to EGFP. When indicated, human Pacer (hPacer-V5) was co-expressed. c and d,
after 48 h, SOD1 aggregation was assessed under non-reducing (−DTT) conditions. Cell extracts were prepared in 1% Triton X-100 buffer or 1%
SDS buffer for Western blot and filter trap assays, respectively. In c HSP90 serves as a loading control. e SOD1 inclusions in NSC34 cells were
assessed by confocal microscopy. Percentages of cells with SOD1WT-EGFP or SOD1G93A-EGFP inclusions are shown. f Percentage of cell death was
quantified at 72 h (SytoxBlue positive, SB+) in NSC34 stable lines expressing shPacer or shCtrl transiently transfected with EGFP, SOD1WTor
SOD1G93A, and hPacer-V5. In e and f statistical analyses were performed using one-way ANOVA and Bonferroni’s post-hoc tests. Mean and SEM
with only statistically significant p-values are shown: *, p ≤ 0.05; **, p ≤ 0.01; and ***, p ≤ 0.001
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and that its loss could lead to a disruption of proteosta-
sis maintenance. In this context, we found that depleting
cells of Pacer not only caused the accumulation of pro-
tein aggregates in our cellular model but also sensitized
cells to death induced by SOD1WT and SOD1G93A ex-
pression. Furthermore, the re-expression of Pacer pro-
tects against this sensitization and even improved the
survival of the NSC34 cells expressing SOD1G93A pro-
tein. Overall, these results suggest that Pacer could be
an important regulator of the cellular proteostasis and
neuronal survival including of vulnerable motoneurons.
Conclusions
In summary, our results suggest a role for Pacer as an
essential component of the autophagy machinery in neu-
rons, especially motoneurons, where it promotes the
clearance of protein aggregates through the autophagy
pathway thereby maintaining proteostasis and sustaining
neural survival. Hence, our results suggest Pacer as a po-
tential new candidate to study its therapeutic effect in
ALS. Furthermore, our experimental results also validate
our unbiased bioinformatic approach, which initially
suggested Pacer as a protein involved in ALS pathology
through a connection with the autophagy pathway. Like
Pacer, many previously uncharacterized genes were iden-
tified as part of a functional context associated with
complex disorders by these type of systems biology ana-
lyses [29, 79, 80]. This approach promises to accelerate
gene and/or pathway discovery in complex diseases and
can help guide experimental studies that may lead to the
identification of biomarkers or therapeutic targets.
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upper panel). Z-stack of confocal images, detection of Pacer, the neuronal
marker NeuN in b, or the astrocytic marker GFAP in c. b and c, Nuclei are
stained with Hoechst. Scale bar: 30 μm. (PPTX 2790 kb)
Additional file 8: Figure S5. Pacer is expressed in MMP9-positive cells
in the presymptomatic spinal cord of SOD1G93A transgenic mice. a, Z-
stack confocal images of Pacer with MMP9 in lumbar spinal cord sections
of non-transgenic controls (non-Tg, 60 days old) and b, presymptomatic
(60 days old) SOD1G93A transgenic mice (SOD1G93A-Tg) at 10X (upper
panel, scale bar: 300 μm), 40X (middle panel, scale bar: 30 μm) and 63X
(lower panel, scale bar: 15 μm) magnification. Doted insets indicate where
higher magnification images were taken. (PPTX 2260 kb)
Additional file 9: Figure S6. Pacer depletion results in detergent insoluble
SOD1 aggregate accumulation. a-b, Densiometric quantification of p62 and
Beclin1 levels in the autophagic flux as shown in Fig. 4a. NSC34 cells depleted
of Pacer and a scrambled shRNA control (shCtrl) construct were compared
(n=3). â-Actin 48 served as a loading control. Statistical analyses were
performed using one-way ANOVA and Bonferroni’s post-hoc tests. Mean and
SEM are shown. c, NSC34 cells depleted of Pacer were transiently co-
transfected with expression vectors for human wild-type or mutant
SOD1G93A fused to EGFP. When indicated, human Pacer (hPacer-V5) was co-
expressed. NP40-detergent insoluble protein aggregates (NP40 insoluble) were
prepared as described in materials and methods. The input is shown as a
reference. â-Actin levels in the input serve as a loading control. d-e, Alignment
of d shRNA A and e shRNA B to the corresponding target region in mRNA of
mouse Pacer and human Pacer. 100% identity between shRNAs A and B to
their respective mouse Pacer target sequences. No significant similarity is
found to the corresponding region of human Pacer mRNA. (PPTX 2110 kb)
Additional file 10: Figure S7. Depletion of Pacer leads to SOD1
aggregate accumulation. a, NSC34 cells were transiently transfected with
constructs for shCtrl, shPacer, EGFP, SOD1WT-EGFP and SOD1G93A-EGFP,
inclusions are shown with white arrows (Representative images of 3
independents experiments). Scale bar 40 μM. b-c, Stable NSC34 cell lines
expressing b shPacer and c shRubicon were established. Knockdown was
confirmed by Western blot. HSP90 and b-Actin were used as loading controls,
respectively. d, Percentage of cell death at 48 h (SytoxBlue positive, SB+) in
NSC34 stable lines expressing shPacer, shRubicon, and shCtrl constructs. Cells
were transiently transfected with plasmids for EGFP or SOD1G93A-EGFP. In d
statistical analyses were performed using one- 49 way ANOVA and
Bonferroni’s post-hoc tests. Mean and SEM with only statistically significant p-
values are shown: *, p ≤ 0.05; and **, p ≤ 0.01. (PPTX 777 kb)
Beltran et al. Molecular Neurodegeneration           (2019) 14:14 Page 15 of 18
Abbreviations
ALS: Amyotrophic lateral sclerosis; FTD: Frontotemporal dementia;
SOD1: Superoxide dismutase 1; TDP43: TAR DNA-binding protein 43
Acknowledgments
We thank Leonardo Rodriguez for technical support in the mouse studies
and the Department of Morphology of the Medical Technology School of
Universidad Mayor for providing tissue processors and microtome.
Funding
This work was funded by Anillo project ACT1109 (PM and CH), FONDECYT
Regular 1150743 (UW), FIDUM 100739 (UW), FONDECYT postdoctoral
fellowship 3140110 (MN), FONDECYT Iniciación 11160288 (MN), Muscular
Dystrophy Association 575897 (DBM), ALS Association 468 (DBM), FONDECYT
Iniciación 11150579 (DBM), FONDECYT Iniciación 11180546 (DRR), FONDECYT
Regular 1161284 (SM). We also thank Millennium Institute No. P09–015-F
FONDAP program 15150012 (CH and SM), the Frick Foundation 20014–15
(CH), ALS Therapy Alliance 2014-F-059 (CH), Muscular Dystrophy Association
382453 (CH), CONICYT-USA 2013–0003, and ALSRP Therapeutic Idea Award
AL150111 (CH). We would like to thank Robert H. Brown (UMASS), Daryl Bo-
sco (UMASS), Diane McKenna-Yasek (UMMS) and Isabel Constantino (Massa-
chusetts General Hospital) for their procurement of human tissue
samples. Research in the group of MJMB is supported by the Vlaams Instituut
voor Biotechnologie (VIB), by grants from the Fonds voor Wetenschappelijk
Onderzoek Vlaanderen (FWO) (G013715N, G044518N, EOS MODEL-IDI
30826052), from the Belgian science policy office (BELSPO)(IAP 7/32) and
from the Flemish Government - accorded to Prof. Vandenabeele (Methusa-
lem BOF09/01M00709 and BOF16/MET_V/007).
Availability of data and materials
The datasets used and/or analyzed during the current study are available.
from the corresponding author on reasonable request.
Authors’ contributions
PM and UW conceived and designed the study. SB, MN, EV, JA, LL, BC, CC,
CB, MFH, SE, JMM, LB, DRR, and DBM performed experiments. SB, MN, CC,
DRR, MJMB, and UW analyzed and interpreted data. SB, MN, and UW drafted
the manuscript. PM, MJMB, DRR, JMM, DBM, CH, and SM edited the
manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Post-mortem frozen spinal cord samples from sALS patients and control
subjects were obtained from the Alzheimer Disease Research Center at
Massachusetts General Hospital and Dr. Robert H. Brown laboratory at the
Neurology Department of University of Massachusetts Medical School under
approved Institutional Review Board protocol (FWA#00004009). We received
de-identified samples in the role of collaborator; therefore, there was no
need for patient consent form.
Consent for publication
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Center for Integrative Biology, Faculty of Science, Universidad Mayor,
Camino la Piramide 5750, P.O.BOX 70086 Santiago, Chile. 2Center for
Genomics and Bioinformatics, Faculty of Science, Universidad Mayor, Camino
la Piramide, 5750 Santiago, Chile. 3Department of Neurological Sciences,
Faculty of Medicine, University of Chile, Santiago, Chile. 4Biomedical
Neuroscience Institute, Faculty of Medicine, University of Chile,
Independencia, 1027 Santiago, Chile. 5Fundación Ciencia & Vida, Zañartu
1482, 7780272 Santiago, Chile. 6Neurounion Biomedical Foundation, 7780272
Santiago, Chile. 7Center for Geroscience, Brain Health and Metabolism
(GERO), Santiago, Chile. 8VIB Center for Inflammation Research,
Technologiepark 927, Zwijnaarde, 9052 Ghent, Belgium. 9Department of
Biomedical Molecular Biology, Ghent University, Technologiepark 927,
Zwijnaarde, 9052 Ghent, Belgium. 10Buck Institute for Research on Aging,
Novato, CA 94945, USA. 11Program of Cellular and Molecular Biology,
Institute of Biomedical Sciences, University of Chile, Independencia, 1027
Santiago, Chile. 12Department of Immunology and Infectious Diseases,
Harvard School of Public Health, Boston, MA 02115, USA. 13Center for the
Study of Biological Complexity, Virginia Commonwealth University,
Richmond, VA 23298, USA.
Received: 30 January 2019 Accepted: 11 March 2019
References
1. Brown RH Jr, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;
377(16):1602.
2. Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic
lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2016.
3. Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to
mechanism. Nature. 2016;539(7628):197–206.
4. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S,
Durnall JC, Williams KL, Buratti E, et al. TDP-43 mutations in familial and
sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668–72.
5. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR,
Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. A
hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome
9p21-linked ALS-FTD. Neuron. 2011;72(2):257–68.
6. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chio A,
Restagno G, Nicolaou N, Simon-Sanchez J, et al. Frequency of the C9orf72
hexanucleotide repeat expansion in patients with amyotrophic lateral
sclerosis and frontotemporal dementia: a cross-sectional study. Lancet
Neurol. 2012;11(4):323–30.
7. Medinas DB, Valenzuela V, Hetz C. Proteostasis disturbance in amyotrophic
lateral sclerosis. Hum Mol Genet. 2017;26(R2):R91–R104.
8. Gao FB, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in
amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder.
EMBO J. 2017;36(20):2931–50.
9. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol.
2010;12(9):814–22.
10. Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F,
Choi AM, Chu CT, Codogno P, Colombo MI, et al. Molecular definitions of
autophagy and related processes. EMBO J. 2017;36(13):1811–36.
11. Kourtis N, Tavernarakis N. Autophagy and cell death in model organisms.
Cell Death Differ. 2009;16(1):21–30.
12. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima
R, Yokoyama M, Mishima K, Saito I, Okano H, et al. Suppression of basal
autophagy in neural cells causes neurodegenerative disease in mice. Nature.
2006;441(7095):885–9.
13. Komatsu M, Ueno T, Waguri S, Uchiyama Y, Kominami E, Tanaka K.
Constitutive autophagy: vital role in clearance of unfavorable proteins in
neurons. Cell Death Differ. 2007;14(5):887–94.
14. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M,
Uchiyama Y, Kominami E, et al. Loss of autophagy in the central nervous
system causes neurodegeneration in mice. Nature. 2006;441(7095):880–4.
15. Vidal RL, Matus S, Bargsted L, Hetz C. Targeting autophagy in
neurodegenerative diseases. Trends Pharmacol Sci. 2014;35(11):583–91.
16. Menzies FM, Fleming A, Caricasole A, Bento CF, Andrews SP, Ashkenazi A,
Fullgrabe J, Jackson A, Jimenez Sanchez M, Karabiyik C, et al. Autophagy
and neurodegeneration: pathogenic mechanisms and therapeutic
opportunities. Neuron. 2017;93(5):1015–34.
17. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y,
Kamada M, Nodera H, Suzuki H, et al. Mutations of optineurin in
amyotrophic lateral sclerosis. Nature. 2010;465(7295):223–6.
18. Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY,
Ouahchi K, Yan J, Azim AC, et al. The gene encoding alsin, a protein with
three guanine-nucleotide exchange factor domains, is mutated in a form of
recessive amyotrophic lateral sclerosis. Nat Genet. 2001;29(2):160–5.
19. Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Muller K, Marroquin
N, Nordin F, Hubers A, Weydt P, et al. Haploinsufficiency of TBK1 causes
familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18(5):631–6.
20. Nassif M, Woehlbier U, Manque PA. The enigmatic role of C9ORF72 in
autophagy. Front Neurosci. 2017;11:442.
Beltran et al. Molecular Neurodegeneration           (2019) 14:14 Page 16 of 18
21. Rudnick ND, Griffey CJ, Guarnieri P, Gerbino V, Wang X, Piersaint JA, Tapia
JC, Rich MM, Maniatis T. Distinct roles for motor neuron autophagy early
and late in the SOD1(G93A) mouse model of ALS. Proc Natl Acad Sci U S A.
2017;114(39):E8294–303.
22. Nassif M, Valenzuela V, Rojas-Rivera D, Vidal R, Matus S, Castillo K, Fuentealba Y,
Kroemer G, Levine B, Hetz C. Pathogenic role of BECN1/Beclin 1 in the
development of amyotrophic lateral sclerosis. Autophagy. 2014;10(7):1256–71.
23. Valenzuela V, Nassif M, Hetz C. Unraveling the role of motoneuron
autophagy in ALS. Autophagy. 2018;14(4):733–7.
24. Gorlov IP, Gallick GE, Gorlova OY, Amos C, Logothetis CJ. GWAS meets
microarray: are the results of genome-wide association studies and gene-
expression profiling consistent? Prostate cancer as an example. PLoS One.
2009;4(8):e6511.
25. Jia P, Ewers JM, Zhao Z. Prioritization of epilepsy associated candidate
genes by convergent analysis. PLoS One. 2011;6(2):e17162.
26. Jia P, Kao CF, Kuo PH, Zhao Z. A comprehensive network and pathway
analysis of candidate genes in major depressive disorder. BMC Syst Biol.
2011;5(Suppl 3):S12.
27. Krishnan A, Zhang R, Yao V, Theesfeld CL, Wong AK, Tadych A, Volfovsky N,
Packer A, Lash a, Troyanskaya OG: Genome-wide prediction and functional
characterization of the genetic basis of autism spectrum disorder. Nat
Neurosc. 2016;19(11):1454–62.
28. Maver A, Peterlin B. Positional integratomic approach in identification of
genomic candidate regions for Parkinson’s disease. Bioinformatics. 2011;
27(14):1971–8.
29. Talwar P, Silla Y, Grover S, Gupta M, Agarwal R, Kushwaha S, Kukreti R.
Genomic convergence and network analysis approach to identify candidate
genes in Alzheimer’s disease. BMC Genomics. 2014;15:199.
30. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the
human autophagy system. Nature. 2010;466(7302):68–76.
31. Cronin S, Tomik B, Bradley DG, Slowik A, Hardiman O. Screening for
replication of genome-wide SNP associations in sporadic ALS. Eur J Hum
Genet. 2009;17(2):213–8.
32. Cheng X, Ma X, Ding X, Li L, Jiang X, Shen Z, Chen S, Liu W, Gong W, Sun Q. Pacer
mediates the function of class III PI3K and HOPS complexes in autophagosome
maturation by engaging Stx17. Mol Cell. 2017;65(6):1029–43 e1025.
33. Cronin S, Blauw HM, Veldink JH, van Es MA, Ophoff RA, Bradley DG, van den
Berg LH, Hardiman O. Analysis of genome-wide copy number variation in
Irish and Dutch ALS populations. Hum Mol Genet. 2008;17(21):3392–8.
34. Blauw HM, Al-Chalabi A, Andersen PM, van Vught PW, Diekstra FP, van Es
MA, Saris CG, Groen EJ, van Rheenen W, Koppers M, et al. A large genome
scan for rare CNVs in amyotrophic lateral sclerosis. Hum Mol Genet. 2010;
19(20):4091–9.
35. Blauw HM, Veldink JH, van Es MA, van Vught PW, Saris CG, van der Zwaag
B, Franke L, Burbach JP, Wokke JH, Ophoff RA, et al. Copy-number variation
in sporadic amyotrophic lateral sclerosis: a genome-wide screen. Lancet
Neurol. 2008;7(4):319–26.
36. Wain LV, Pedroso I, Landers JE, Breen G, Shaw CE, Leigh PN, Brown RH,
Tobin MD, Al-Chalabi A. The role of copy number variation in susceptibility
to amyotrophic lateral sclerosis: genome-wide association study and
comparison with published loci. PLoS One. 2009;4(12):e8175.
37. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD,
Caliendo J, Hentati A, Kwon YW, Deng HX, et al. Motor neuron
degeneration in mice that express a human Cu,Zn superoxide dismutase
mutation. Science. 1994;264(5166):1772–5.
38. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant
transgenic mice develop features of ALS and frontotemporal lobar
degeneration. Proc Natl Acad Sci U S A. 2009;106(44):18809–14.
39. Herdewyn S, Cirillo C, Van Den Bosch L, Robberecht W, Vanden Berghe P, Van
Damme P. Prevention of intestinal obstruction reveals progressive
neurodegeneration in mutant TDP-43 (A315T) mice. Mol Neurodegener. 2014;9:24.
40. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M,
Schneider MD, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-
dependent autophagy. Cell. 2005;122(6):927–39.
41. Turner BJ, Atkin JD, Farg MA, Zang DW, Rembach A, Lopes EC, Patch JD, Hill
AF, Cheema SS. Impaired extracellular secretion of mutant superoxide
dismutase 1 associates with neurotoxicity in familial amyotrophic lateral
sclerosis. J Neurosci. 2005;25(1):108–17.
42. Cortez C, Real F, Yoshida N. Lysosome biogenesis/scattering increases host
cell susceptibility to invasion by Trypanosoma cruzi metacyclic forms and
resistance to tissue culture trypomastigotes. Cell Microbiol. 2016;18(5):748–60.
43. Wanker EE, Scherzinger E, Heiser V, Sittler A, Eickhoff H, Lehrach H.
Membrane filter assay for detection of amyloid-like polyglutamine-
containing protein aggregates. Methods Enzymol. 1999;309:375–86.
44. Wang J, Xu G, Borchelt DR. Mapping superoxide dismutase 1 domains of
non-native interaction: roles of intra- and intermolecular disulfide bonding
in aggregation. J Neurochem. 2006;96(5):1277–88.
45. Hetz C, Thielen P, Matus S, Nassif M, Court F, Kiffin R, Martinez G, Cuervo
AM, Brown RH, Glimcher LH. XBP-1 deficiency in the nervous system
protects against amyotrophic lateral sclerosis by increasing autophagy.
Genes Dev. 2009;23(19):2294–306.
46. Tokuda E, Brannstrom T, Andersen PM, Marklund SL. Low autophagy
capacity implicated in motor system vulnerability to mutant superoxide
dismutase. Acta Neuropathol Commun. 2016;4:6.
47. Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, Colby G, Gebreab F,
Gygi MP, Parzen H, et al. Architecture of the human interactome defines protein
communities and disease networks. Nature. 2017;545(7655):505–9.
48. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo
Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al. Guidelines for
the use and interpretation of assays for monitoring autophagy (3rd edition).
Autophagy. 2016;12(1):1–222.
49. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S,
Spencer B, Rockenstein E, Levine B, et al. The autophagy-related protein
beclin 1 shows reduced expression in early Alzheimer disease and regulates
amyloid beta accumulation in mice. J Clin Invest. 2008;118(6):2190–9.
50. Bargsted L, Medinas DB, Martinez Traub F, Rozas P, Munoz N, Nassif M, Jerez
C, Catenaccio A, Court FA, Hetz C, et al. Disulfide cross-linked multimers of
TDP-43 and spinal motoneuron loss in a TDP-43(A315T) ALS/FTD mouse
model. Sci Rep. 2017;7(1):14266.
51. Kaplan A, Spiller KJ, Towne C, Kanning KC, Choe GT, Geber A, Akay T,
Aebischer P, Henderson CE. Neuronal matrix metalloproteinase-9 is a
determinant of selective neurodegeneration. Neuron. 2014;81(2):333–48.
52. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P,
Goolsby H, Fontaine BA, Lemay N, McKenna-Yasek D, et al. Wild-type and
mutant SOD1 share an aberrant conformation and a common pathogenic
pathway in ALS. Nat Neurosci. 2010;13(11):1396–403.
53. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin
M, Jacobsson J, Rosquist R, Marklund SL, Brannstrom T. Novel antibodies
reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS
One. 2010;5(7):e11552.
54. Medinas DB, Rozas P, Martinez Traub F, Woehlbier U, Brown RH, Bosco DA,
Hetz C. Endoplasmic reticulum stress leads to accumulation of wild-type
SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis.
Proc Natl Acad Sci U S A. 2018;115(32):8209–14.
55. Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, van
Criekinge W, de Meyer T, Denil S, van der Zee AGJ, et al. Discovery of new
methylation markers to improve screening for cervical intraepithelial
neoplasia grade 2/3. Clin Epigenetics. 2016;8:29.
56. Huisman C, van der Wijst MG, Schokker M, Blancafort P, Terpstra MM, Kok K,
van der Zee AG, Schuuring E, Wisman GB, Rots MG. Re-expression of
selected epigenetically silenced candidate tumor suppressor genes in
cervical Cancer by TET2-directed demethylation. Mol Ther. 2016;24(3):536–47.
57. Yang N, Eijsink JJ, Lendvai A, Volders HH, Klip H, Buikema HJ, van Hemel BM,
Schuuring E, van der Zee AG, Wisman GB. Methylation markers for CCNA1
and C13ORF18 are strongly associated with high-grade cervical
intraepithelial neoplasia and cervical cancer in cervical scrapings. Cancer
Epidemiol Biomarkers Prev. 2009;18(11):3000–7.
58. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M,
Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al.
Expanded GGGGCC hexanucleotide repeat in noncoding region of
C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;
72(2):245–56.
59. Morgan S, Shatunov A, Sproviero W, Jones AR, Shoai M, Hughes D, Al
Khleifat A, Malaspina A, Morrison KE, Shaw PJ, et al. A comprehensive
analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK.
Brain. 2017;140(6):1611–8.
60. Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B,
Tudor EL, Smith BN, Klasen C, Miller CC, et al. Overexpression of human
wild-type FUS causes progressive motor neuron degeneration in an age-
and dose-dependent fashion. Acta Neuropathol. 2013;125(2):273–88.
61. Sabatelli M, Moncada A, Conte A, Lattante S, Marangi G, Luigetti M, Lucchini
M, Mirabella M, Romano A, Del Grande A, et al. Mutations in the 3′
Beltran et al. Molecular Neurodegeneration           (2019) 14:14 Page 17 of 18
untranslated region of FUS causing FUS overexpression are associated with
amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22(23):4748–55.
62. Gitcho MA, Bigio EH, Mishra M, Johnson N, Weintraub S, Mesulam M,
Rademakers R, Chakraverty S, Cruchaga C, Morris JC, et al. TARDBP 3′-UTR
variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-
43 proteinopathy. Acta Neuropathol. 2009;118(5):633–45.
63. Pehar M, Harlan BA, Killoy KM, Vargas MR. Role and therapeutic potential of
astrocytes in amyotrophic lateral sclerosis. Curr Pharm Des. 2017;23(33):
5010–21.
64. Vinsant S, Mansfield C, Jimenez-Moreno R, Del Gaizo MV, Yoshikawa M,
Hampton TG, Prevette D, Caress J, Oppenheim RW, Milligan C.
Characterization of early pathogenesis in the SOD1(G93A) mouse model of
ALS: part II, results and discussion. Brain Behav. 2013;3(4):431–57.
65. Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, Court FA, van
Zundert B, Hetz C. Trehalose delays the progression of amyotrophic lateral
sclerosis by enhancing autophagy in motoneurons. Autophagy. 2013;9(9):
1308–20.
66. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S,
Erdin SU, Huynh T, Medina D, Colella P, et al. TFEB links autophagy to
lysosomal biogenesis. Science. 2011;332(6036):1429–33.
67. Sun Q, Westphal W, Wong KN, Tan I, Zhong Q. Rubicon controls endosome
maturation as a Rab7 effector. Proc Natl Acad Sci U S A. 2010;107(45):
19338–43.
68. Tabata K, Matsunaga K, Sakane A, Sasaki T, Noda T, Yoshimori T. Rubicon
and PLEKHM1 negatively regulate the endocytic/autophagic pathway via a
novel Rab7-binding domain. Mol Biol Cell. 2010;21(23):4162–72.
69. Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotori N, Maejima I,
Shirahama-Noda K, Ichimura T, Isobe T, et al. Two Beclin 1-binding proteins,
Atg14L and Rubicon, reciprocally regulate autophagy at different stages.
Nat Cell Biol. 2009;11(4):385–96.
70. Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, Heintz N, Yue Z. Distinct
regulation of autophagic activity by Atg14L and Rubicon associated with
Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol. 2009;11(4):468–76.
71. Martinez J, Malireddi RK, Lu Q, Cunha LD, Pelletier S, Gingras S, Orchard R,
Guan JL, Tan H, Peng J, et al. Molecular characterization of LC3-associated
phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy
proteins. Nat Cell Biol. 2015;17(7):893–906.
72. Wilhelm T, Byrne J, Medina R, Kolundzic E, Geisinger J, Hajduskova M,
Tursun B, Richly H. Neuronal inhibition of the autophagy nucleation
complex extends life span in post-reproductive C. Elegans. Genes Dev. 2017;
31(15):1561–72.
73. Carnio S, LoVerso F, Baraibar MA, Longa E, Khan MM, Maffei M, Reischl M,
Canepari M, Loefler S, Kern H, et al. Autophagy impairment in muscle
induces neuromuscular junction degeneration and precocious aging. Cell
Rep. 2014;8(5):1509–21.
74. Cuervo AM. Autophagy and aging: keeping that old broom working. Trends
Genet. 2008;24(12):604–12.
75. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell. 2011;
146(5):682–95.
76. Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, Nishihara M. Possible
involvement of lysosomal dysfunction in pathological changes of the brain
in aged progranulin-deficient mice. Acta neuropathologica
communications. 2014;2:78.
77. Xie Y, Zhou B, Lin MY, Wang S, Foust KD, Sheng ZH. Endolysosomal deficits
augment mitochondria pathology in spinal motor neurons of asymptomatic
fALS mice. Neuron. 2015;87(2):355–70.
78. Kabuta T, Suzuki Y, Wada K. Degradation of amyotrophic lateral sclerosis-
linked mutant Cu,Zn-superoxide dismutase proteins by macroautophagy
and the proteasome. J Biol Chem. 2006;281(41):30524–33.
79. Johnson MR, Shkura K, Langley SR, Delahaye-Duriez A, Srivastava P, Hill WD,
Rackham OJ, Davies G, Harris SE, Moreno-Moral A, et al. Systems genetics
identifies a convergent gene network for cognition and
neurodevelopmental disease. Nat Neurosci. 2016;19(2):223–32.
80. Monti C, Colugnat I, Lopiano L, Chio A, Alberio T. Network analysis identifies
disease-specific pathways for Parkinson’s disease. Mol Neurobiol. 2016.
Beltran et al. Molecular Neurodegeneration           (2019) 14:14 Page 18 of 18
